Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS) INCOME	$ (25,712,343)	$ 10,483,429	$ (40,910,030)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	531,316	516,117	417,205
Issuance of common stock options and warrants to nonemployees for services			449,641
Issuance of convertible notes and preferred stock in legal settlement	9,000,000
Issuance of common stock for services	214,123	1,241,026	1,561,343
Premium on loan			341,454
Loan premium adjustment			489,776
Amortization of loan premium		(3,282)	(338,172)
Modification of stock options and warrants	135,988	227,921	6,142
Issuance of stock to employees			685,858
Loss on conversion of convertible notes			2,145,754
Employee option cost	1,535,329	1,316,399	1,699,448
Common stock contributed to 401(k) plan	150,865	112,325	57,829
Warrants issued in consideration for loan			65,796
Impairment loss on abandonment of patents	9,016	13,877	138,525
Loss on retired equipment	2,828	2,323	270
Deferred rent	(3,699)	(6,080)	7,688
Amortization of discount on convertible note			193,980
Gain/loss on derivative instruments	(4,432,148)	(28,843,772)	25,514,667
Change in assets and liabilities:
(Increase)/decrease in deposits	(1,670,917)	1,585,064	4,764
Increase in receivables	(457,337)
Decrease in deferred rent	629,682	955,842	622,350
Increase in prepaid expenses	(1,729,812)	(258,747)	(12,763)
Increase in inventory for R&D and manufacturing	(94,948)	(1,076,760)	(4,304)
(Decrease)/increase in accounts payable	(788,254)	693,799	343,208
(Decrease)/increase in accrued expenses	147,919	125,031	(14,514)
Decrease in accrued interest on convertible debt			(2,674)
Increase in deferred revenue		125,000
(Decrease)/increase in amount due to employees	(23,019)	(3,719)	13,450
(Decrease)/increase in deposits held		(10,000)	10,000
NET CASH USED IN OPERATING ACTIVITIES	(22,555,411)	(12,804,207)	(6,513,309)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additional investment in manufacturing facility		(32,059)	(505,225)
Decrease in restricted cash	21,357	47,195	919,100
Sale of investments in available-for-sale securities			200,000
Purchases of equipment	(216,761)	(493,736)	(191,868)
Expenditures for Patent costs	(122,706)	(25,340)	(53,290)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(318,110)	(503,940)	368,717
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,936,284		32,242,716
Proceeds from exercise of stock options and warrants	679,588	6,308,874	8,681,254
Proceeds from short-term loan			3,104,057
Repayment of short-term loan			(2,200,000)
Payment for repurchase of preferred stock	(4,050,000)		(754,250)
Costs for equity related transactions			(2,072,927)
NET CASH PROVIDED BY FINANCING ACTIVITIES	565,872	6,308,874	39,000,850
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(22,307,649)	(6,999,273)	32,856,258
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR	26,568,243	33,567,516	711,258
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	4,260,594	26,568,243	33,567,516
Conversion of convertible debt into common stock:
Decrease in convertible debt			1,206,341
Increase in common stock			(30,159)
Increase in additional paid-in capital			(1,176,182)
Total	0	0	0
Conversion of interest on convertible debt into common stock:
Decrease in accrued liabilities			42,885
Increase in common stock			(1,774)
Increase in additional paid-in capital			(41,111)
Total	0	0	0
Payment of convertible debt principal with common stock:
Decrease in convertible debt			285,000
Increase in common stock			(9,728)
Increase in additional paid-in capital			(275,272)
Total	0	0	0
Issuance of warrants:
Increase in derivative liabilities			(8,877,217)
Increase in discount on notes payable			245,000
Decrease in additional paid-in capital			8,632,217
Total	0	0	0
Exercise of derivative liabilities:
Decrease in derivative liabilities	202,830	5,510,490
Increase in additional paid-in capital	(202,830)	(5,510,490)
Total	0	0	0
Modification of warrants:
Increase in additional paid-in capital		(1,532,456)	(24,061)
Decrease in additional paid-in capital		1,532,456	24,061
Total	0	0	0
Patent costs included in accounts payable:
Increase in patent costs	28,531		7,285
Increase in accounts payable	(28,531)		(7,285)
Total	0	0	0
Equipment costs included in accounts payable:
Increase in research and office equipment	1,291	10,436	15,147
Increase in accounts payable for Equipment costs	(1,291)	(10,436)	(15,147)
Total	0	0	0
Warrants issued for loan:
Increase in debt discount			65,796
Increase in additional paid-in capital			(65,796)
Total	0	0	0
Stock modification recorded as dividend:
Increase in common stock			(11,667)
Increase additional paid-in capital			(479,061)
Increase accumulated deficit			490,728
Total	0	0	0
Adoption of ASC 815-40:
Increase in derivative liabilities		(6,186,343)
Increase in accumulated deficit		6,186,343
Total	0	0	0
Dismissal of liability for overpayment:
Decrease in accrued expenses	81,395
Increase in additional paid-in capital	(81,395)
Total	0	0	0
SUPPLEMENTAL INFORMATION ON NONCASH TRANSACTIONS:
Cash expenditures for interest expense	$ 195,980	$ 162,326	$ 115,559